FRANKFURT: Bayer AG struck an US$875mil deal to acquire British women’s health biotech Kandy Therapeutics Ltd in a move to expand its pharmaceuticals division before the expiration of patents on existing medicines.
The German drug and chemical company agreed to pay US$425mil upfront and potential milestone payments of US$450mil until the launch of Kandy’s experimental treatment for menopause symptoms.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
